FDA Clears Phase 2b Trial of Teverelix for Advanced Prostate Cancer Patients with High Cardiovascular Risk

Medicus Pharma Ltd. (搜索)搜索该公司 has received FDA clearance to proceed with a Phase 2b dose-optimization study of Teverelix查看药品详情, an investigational next-generation long-acting GnRH antagonist, for men with advanced prostate cancer and elevated cardiovascular risk. The "study may proceed" clearance marks a significant milestone for the precision-guided biotech company's development strategy targeting an underserved patient population.

Study Design and Primary Objectives

The Phase 2b study is an open-label trial enrolling 40 men with advanced prostate cancer appropriate for androgen deprivation therapy (ADT). Participants will receive a loading regimen of 180 mg intramuscular plus two 180 mg subcutaneous injections (total 540 mg), followed by two 180 mg subcutaneous injections (360 mg total) on Day 29 and every six weeks thereafter. Total treatment duration is approximately 22 weeks.

The primary endpoint is confirmation of medical castration by Day 29 with sustained suppression through Day 155, with a target probability exceeding 90%. The study will also evaluate durability of testosterone suppression, degree and consistency of FSH suppression, and cardiovascular safety to enable a registrational Phase 3 development pathway aligned with prior FDA guidance.

Differentiated Mechanism Addresses Cardiovascular Risk

Teverelix查看药品详情 trifluoroacetate is formulated as a microcrystalline suspension that provides immediate receptor antagonism, enabling rapid suppression of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and downstream sex hormones without flare. This mechanism differs from GnRH agonists, which induce an initial testosterone surge before suppression occurs.

The cardiovascular implications are particularly relevant given that cardiovascular disease remains a leading cause of non-cancer mortality in prostate cancer, accounting for approximately 30% of deaths. The risk is further amplified during ADT, particularly among patients with pre-existing cardiovascular disease. Clinical and observational data indicate that such patients may experience a five- to six-fold higher incidence of major adverse cardiovascular events (MACE) when treated with GnRH agonists compared with GnRH antagonists.

Targeted Patient Population and Market Opportunity

Teverelix查看药品详情 is being developed specifically for advanced prostate cancer patients with objectively defined cardiovascular risk, including those with recent MACE or severe subclinical atherosclerosis, as measured by a coronary artery calcium (CAC) score greater than 400 in conjunction with elevated ASCVD risk.

Approximately 300,000 to 500,000 men in the United States are living with advanced prostate cancer, representing an estimated annual market opportunity exceeding US$4 billion. Dr. Raza Bokhari, Medicus Executive Chairman & CEO, stated, "Our development strategy is intentionally focused on a population that remains underserved by existing therapies. If successful, we believe Teverelix查看药品详情 has the potential to become a best-in-class GnRH antagonist and the first hormone therapy specifically supported by a Cardiovascular-risk–focused label in this setting."

Regulatory Pathway and Strategic Positioning

Based on prior interactions with the FDA, Medicus has aligned on the development indication of "hormone therapy for advanced prostate cancer patients with increased cardiovascular risk." The Company has defined a clear Phase 3 framework designed to evaluate sustained castration efficacy alongside cardiovascular outcomes.

This differentiated, CV-risk–focused labeling strategy has the potential to establish Teverelix查看药品详情 as a new therapeutic backbone for patients in whom cardiovascular safety is a critical determinant of treatment choice. In parallel, Medicus maintains a complete European clinical trial authorization framework under the Clinical Trial Information System (CTIS) for the advanced prostate cancer program, supporting global development.

Clinical Development History and Safety Profile

Prior Teverelix查看药品详情 studies have not demonstrated significant cardiovascular safety signals to date. In September 2020, Antev (acquired by Medicus in August 2025) completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression in 48 healthy male volunteers.

In February 2023, Antev completed a Phase 2a study in 50 patients with advanced prostate cancer, where Teverelix查看药品详情 achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%), though the secondary endpoint of maintaining this rate above 90% was not met, with the probability dropping to 82.5% by Day 42.

The FDA reviewed the Phase 1 and Phase 2a data in January 2023 and provided written guidance on Antev's proposed Phase 3 trial design for Teverelix查看药品详情. In December 2023, the FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients, and in November 2024, the FDA approved the Phase 2b study design in acute urinary retention relapse covering 390 patients.

Strategic Development and Partnership Focus

Medicus' development strategy is to advance select programs through Phase 2 proof-of-concept and pursue licensing or strategic partnerships with established pharmaceutical companies for late-stage development and commercialization. The Company believes the Teverelix查看药品详情 program is increasingly well positioned for strategic partnership discussions, particularly with organizations seeking differentiated late-stage oncology assets supported by a clear regulatory and labeling strategy.